The 160-gene NGS panel for solid lung tumors packages a broad genomic profile into one sequencing workflow, making it attractive to reference laboratories that need high throughput without managing many narrow assays. For B2B procurement, the deciding factors are not only the gene list but also consumable economics, turnaround, and supplier reliability. This article reviews the sourcing criteria that keep a high-volume lab running.
A single library prep enriches the 160 genes, which span driver mutations, copy changes, and relevant fusions across lung tumor biology. Sequencing output is interpreted by annotation software that maps findings to targeted therapy and trial options. Because the panel is fixed, lot performance is consistent and laboratories can standardize quality control across every run rather than recalibrating for each individual marker.
The panel fits advanced non-small-cell lung cancer where broad profiling informs first and later lines, and where tissue is sufficient for a comprehensive assay. It is also used when a single broad test is preferred over successive focused tests. Distributors should describe it as a throughput solution, not a single-marker test, because its advantage is coverage and reproducibility at scale.
Operationally, the lab defines sample acceptance, the minimum tumor content, and the reporting turnaround, commonly one to two weeks. Buyers should confirm the platform compatibility, the automation level of library prep, and whether the supplier supports the analysis software. Clear service-level commitments protect downstream treatment scheduling and reduce avoidable sample retakes.
Reagents are cold-chain sensitive and must arrive under 2 to 8°C with monitored logging; kits should ship with lot certificates. Sourcing decisions should weigh minimum order quantity against storage shelf life, because overstocking temperature-sensitive consumables raises waste and cost. Ask for reference-material support, training, and a stated reagent stability window before contracting a high-volume supply agreement.
Reference laboratories should also confirm the supplier publishes a clear per-run quality dashboard so batch failures are caught before patient reports are released, and that consumable lot changes are flagged in advance to protect throughput.
Buyers should request a forecast of reagent lead times during peak seasons so planned test volume is not interrupted by unexpected stockouts or backorders.
Q: What throughput factors matter most when sourcing this panel? Q: How should minimum order quantity be balanced against reagent shelf life? Q: Which sample types are accepted by the 160-gene workflow? Q: Does the supplier provide the interpretation software license?
The 160-gene NGS panel for solid lung tumors packages a broad genomic profile into one sequencing workflow, making it attractive to reference laboratories that need high throughput without managing many narrow assays. For B2B procurement, the deciding factors are not only the gene list but also consumable economics, turnaround, and supplier reliability. This article reviews the sourcing criteria that keep a high-volume lab running.
A single library prep enriches the 160 genes, which span driver mutations, copy changes, and relevant fusions across lung tumor biology. Sequencing output is interpreted by annotation software that maps findings to targeted therapy and trial options. Because the panel is fixed, lot performance is consistent and laboratories can standardize quality control across every run rather than recalibrating for each individual marker.
The panel fits advanced non-small-cell lung cancer where broad profiling informs first and later lines, and where tissue is sufficient for a comprehensive assay. It is also used when a single broad test is preferred over successive focused tests. Distributors should describe it as a throughput solution, not a single-marker test, because its advantage is coverage and reproducibility at scale.
Operationally, the lab defines sample acceptance, the minimum tumor content, and the reporting turnaround, commonly one to two weeks. Buyers should confirm the platform compatibility, the automation level of library prep, and whether the supplier supports the analysis software. Clear service-level commitments protect downstream treatment scheduling and reduce avoidable sample retakes.
Reagents are cold-chain sensitive and must arrive under 2 to 8°C with monitored logging; kits should ship with lot certificates. Sourcing decisions should weigh minimum order quantity against storage shelf life, because overstocking temperature-sensitive consumables raises waste and cost. Ask for reference-material support, training, and a stated reagent stability window before contracting a high-volume supply agreement.
Reference laboratories should also confirm the supplier publishes a clear per-run quality dashboard so batch failures are caught before patient reports are released, and that consumable lot changes are flagged in advance to protect throughput.
Buyers should request a forecast of reagent lead times during peak seasons so planned test volume is not interrupted by unexpected stockouts or backorders.
Q: What throughput factors matter most when sourcing this panel? Q: How should minimum order quantity be balanced against reagent shelf life? Q: Which sample types are accepted by the 160-gene workflow? Q: Does the supplier provide the interpretation software license?
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
